Welcome to our dedicated page for Utime news (Ticker: WTO), a resource for investors and traders seeking the latest updates and insights on Utime stock.
UTime Ltd (NASDAQ: WTO) provides investors and industry observers with centralized access to official company announcements and market-moving developments. This resource aggregates verified news across the company's core operations in mobile device manufacturing, medical wearable technologies, and digital distribution platforms.
Users gain efficient tracking of financial disclosures including quarterly earnings, annual reports, and regulatory filings. The collection also features product launch updates, strategic partnership announcements, and operational expansion news relevant to emerging markets. All content is sourced from company-published materials and reputable financial news outlets.
Key categories include earnings call transcripts, leadership updates, manufacturing capacity changes, and R&D milestones in health technology. The chronological organization enables quick identification of recent developments while maintaining historical context for long-term analysis.
Bookmark this page for streamlined monitoring of UTime's progress in consumer electronics innovation and smart healthcare solutions. Combine regular visits with SEC filings and market data tools for comprehensive investment research.
UTime (Nasdaq: WTO) announced a 1-for-100 reverse stock split of its Class A ordinary shares, effective 12:01 a.m. ET on November 21, 2025. Shares will trade on a split-adjusted basis at market open on November 21, 2025 under the ticker WTO. The company said the reverse split is intended to increase the per-share trading price to help regain compliance with Nasdaq's minimum bid price requirement and to better position the stock for long-term growth and institutional participation.
No fractional shares will be issued; any fractional share resulting from the adjustment will be rounded up to the nearest whole share. Brokerages and book-entry positions will be automatically updated to reflect the reverse split.
UTime Limited (Nasdaq: WTO) said on Nov 5, 2025 that it is expanding distribution of its health-focused smart wearables to additional international markets through existing global channels and partners.
The company plans to leverage its mobile-device experience in supply chain management and product development to introduce newly launched smartwatches and smart rings overseas, targeting markets where it already has business connections and seeking new partnerships.
Management emphasized the products' combination of functional design and cost-effectiveness as competitive advantages for gaining share in international personal-health markets.
UTime (Nasdaq: WTO) announced ongoing research into applying AI to health data analysis from wearable devices on November 3, 2025. The company is developing AI algorithm models to analyze continuous physiological signals from smart watches and rings.
Key research directions include building hypertension risk assessment models that integrate blood pressure, heart rate, activity and sleep, and conducting cardiovascular trend assessments via pulse wave morphology analysis. UTime says these AI functions are intended as health insights and risk-management references, not medical diagnoses. Management framed the work as a long-term R&D investment to generate earlier, deeper user health insights.
UTime Limited (Nasdaq: WTO) on October 30, 2025 released a smart ring designed for unobtrusive nighttime and long‑term continuous health monitoring.
The ring measures skin temperature, SpO2, respiratory rate, and heart rate variability (HRV) and targets sleep quality assessment with detailed, unobtrusive sleep analysis reports. It also supports daily activity tracking and female health cycle management. Management described the ring as a complementary, discreet alternative to smartwatches for continuous monitoring in specific scenarios.
UTime (Nasdaq: WTO) launched a smartwatch with integrated blood pressure monitoring on Oct 28, 2025, expanding its health tech product lineup.
The device uses the oscillometric method with an integrated micro air pump and high-precision pressure sensor, and it holds a China NMPA Class II Medical Device Registration (Registration Certificate No. Guangdong Instrument Note No. 20162070928). The watch also reports heart rate, blood oxygen saturation, sleep analysis, and multiple sports modes while emphasizing wearing comfort and interactive features like voice reminders.
UTime (NASDAQ: WTO) announced an October 23, 2025 Memorandum of Understanding to co-develop a digital eldercare services platform with Hainan Fuxinyi Investment over a three-year collaboration.
Under the MOU UTime will provide device design, product development and manufacturing; Fuxinyi will integrate eldercare service providers and community resources. A pilot rollout is planned in Nanning, Guangxi province with phased expansion across southern China. The company frames the MOU as a strategic shift from consumer devices toward healthcare and the "silver economy" to pursue long-term growth opportunities.
UTime (Nasdaq: WTO) priced a registered direct offering of 22,727,275 units at $1.10 per unit, each unit comprising one Class A ordinary share and one Series A warrant. Gross proceeds are expected to be approximately $25.0 million before placement agent fees and expenses. Each Warrant is immediately exercisable at $1.10 and expires six months after issuance. The offering is expected to close on or about October 17, 2025, subject to customary conditions, and is being placed by Univest Securities under a Form F-3 shelf registration declared effective June 10, 2024.
UTime Limited (NASDAQ: UTME) has issued an urgent statement addressing unauthorized press releases published on September 11, 2025, which falsely claimed changes in the company's management and board composition. The company confirms that CEO and Chairman Hengcong Qiu and all board members remain in their positions.
The fraudulent releases were allegedly distributed by a former employee who previously managed investor relations. UTime is taking immediate action, including notifying the SEC about fraudulent filings and involving proper authorities to investigate the matter. The company's board continues to consist of Minfei Bao, Hengcong Qiu, Xiaoqian Jia, Hailin Xie, and Yanzhi Wang.
UTime Limited (NASDAQ: UTME) has announced significant changes to its Board of Directors and confirmed its corporate governance stability. The company disclosed the resignation of four directors on September 4, 2025, followed by the appointment of five new directors on September 8-9, 2025.
Key appointments include Wang Tianlong as CEO and Chairman of the Board, along with three independent directors: Ouyang Xuan (Audit Committee Chair), Tong Shirong (Compensation Committee Chair), and Liu Zhongping (Nomination and Governance Committee Chair). Wu Xiaoxia was also appointed as Director.
The company emphasizes that its governance mechanisms remain intact, business operations continue normally, and it maintains commitment to NASDAQ compliance and transparency.
UTime Limited (NASDAQ: WTO), a Chinese mobile device manufacturer and technology company, has announced the change of its official website to http://wtoworld.com effective September 9, 2025.
The company also issued a statement addressing an unauthorized SEC filing regarding its management and board composition. UTime focuses on designing, developing, producing, and selling mobile devices in China and international markets, with an emphasis on cost-effective products for a broad customer base.
FAQ
What is the current stock price of Utime (WTO)?
What is the market cap of Utime (WTO)?
